Cyclacel Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Cyclacel Pharmaceuticals Inc cash flow-to-debt ratio. Cyclacel Pharmaceuticals Inc (CYCC) has a Cash Flow-to-Debt Ratio of -1.37x as of June 2025, meaning its operating cash flow of $-1.06K could theoretically repay -1% of its total liabilities ($770.00) in one year. Check earnings quality score of Cyclacel Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cyclacel Pharmaceuticals Inc (2003–2024)
Cash flow-to-debt ratio of Cyclacel Pharmaceuticals Inc from 2003 to 2024. Historical debt coverage capacity for Cyclacel Pharmaceuticals Inc across 22 annual periods. Check CYCC cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Cyclacel Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2003–2024)
Cyclacel Pharmaceuticals Inc cash flow-to-debt ratio by year from 2003 to 2024. Year-by-year debt coverage analysis for Cyclacel Pharmaceuticals Inc. For the full cash flow conversion analysis, see Cyclacel Pharmaceuticals Inc (CYCC) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.27x | $-7.99 Million | $6.27 Million | ▲ +35.1% |
| 2023 | -1.97x | $-16.11 Million | $8.20 Million | ▲ +28.1% |
| 2022 | -2.73x | $-20.83 Million | $7.62 Million | ▲ +19.7% |
| 2021 | -3.41x | $-18.54 Million | $5.44 Million | ▼ -52.1% |
| 2020 | -2.24x | $-7.93 Million | $3.54 Million | ▲ +14.4% |
| 2019 | -2.62x | $-9.45 Million | $3.61 Million | ▼ -77.7% |
| 2018 | -1.47x | $-6.70 Million | $4.55 Million | ▲ +16.6% |
| 2017 | -1.77x | $-7.48 Million | $4.24 Million | ▲ +5.6% |
| 2016 | -1.87x | $-10.08 Million | $5.39 Million | ▲ +23.3% |
| 2015 | -2.44x | $-14.46 Million | $5.93 Million | ▼ -0.4% |
| 2014 | -2.43x | $-18.70 Million | $7.70 Million | ▼ -0.1% |
| 2013 | -2.43x | $-18.20 Million | $7.50 Million | ▼ -88.2% |
| 2012 | -1.29x | $-12.04 Million | $9.34 Million | ▲ +40.0% |
| 2011 | -2.15x | $-13.98 Million | $6.50 Million | ▲ +12.4% |
| 2010 | -2.46x | $-16.04 Million | $6.54 Million | ▼ -58.7% |
| 2009 | -1.55x | $-15.19 Million | $9.82 Million | ▲ +46.6% |
| 2008 | -2.90x | $-29.91 Million | $10.31 Million | ▼ -124.8% |
| 2007 | -1.29x | $-23.14 Million | $17.94 Million | ▲ +40.2% |
| 2006 | -2.16x | $-20.17 Million | $9.36 Million | ▲ +31.4% |
| 2005 | -3.14x | $-21.51 Million | $6.84 Million | ▼ -71.2% |
| 2004 | -1.84x | $-21.09 Million | $11.48 Million | ▼ -888.2% |
| 2003 | -0.19x | $-15.49 Million | $83.34 Million | — |